Further research should focus on evaluating HER-2/neu expression in relation to HPV genotype and viral load, assessing the efficacy of HER-2/neu-targeted therapies in cervical carcinoma, particularly in advanced and recurrent cases, and exploring the molecular mechanisms underlying HER-2/neu overexpression in cervical cancer and its interplay with other oncogenic pathways. The gene discussed is ERBB2; the disease is cervical cancer.